SmartClot: Personalized platform for the combined evaluation of platelet and coagulation factor in haemostasis or during antithrombbotic therapy

Informazioni relative al progetto

Smart Clot

ID dell’accordo di sovvenzione: 827998

DOI

10.3030/827998

Progetto chiuso

Data della firma CE 2 Agosto 2018

Data di avvio 1 Agosto 2018

Data di completamento 30 Novembre 2018

Finanziato da

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Costo totale

€ 71 429,00

Contributo UE

€ 50 000,00

Coordinato da

SEDICIDODICI SRL
Italy

Periodic Reporting for period 1 - Smart Clot (SmartClot: Personalized platform for the combined evaluation of platelet and coagulation factor in haemostasis or during antithrombbotic therapy)

Periodo di rendicontazione: 2018-08-01 al 2018-11-30

Sintesi del contesto e degli obiettivi generali del progetto

Cardiovascular diseases (CVDs) are the leading cause of mortality globally, causing 3.9 million deaths annually in EU. However, early identification and control of patients at high risk of suffering CVDs can potentially reduce these figures.
We at SediciDodici have developed an innovative in-vitro diagnostic device called Smart Clot, which can provide a global quantitative assessment of platelet and coagulation function in blood samples within minutes from obtaining patients´ specimen, which can be life-saving in conditions of surgical or medical emergency. Based on the current prototype, which consists on an analysis equipment and a perfusion cartridge mostly used manually, we intend to produce a low-cost and improved version. Thus, the project will be oriented towards obtaining the automation and scale-up of the platform, software development and implementation, and clinical validation.
The FS confirms the uniqueness of our innovation, its technical feasibility and commercial profitability.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

Technical FS defines the current prototype (TRL 7), and the improvement to be done, outlines and validates the work plan to scale-up the platform and gain capability for large deployment once we reach the market, and analyses technical risks and their contingency and mitigation measures.
Commercial FS offers an in-depth study on cardiovascular medical device market, evaluates the existing solutions to diagnose CVDs (competitors) and the regulatory and certification framework, conducts a IPR study to confirm our freedom to operate, and defines an exploitation and dissemination plan.
Financial FS makes a production cost assessment of the project (~€2.5 million) and offers a business projections analysis for the first 5-years of commercialization.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

Smart Clot will reduce burden of CVDs by improving the medical prevention technology already available. Additionally, it will also have a positive impact for the company´s growth, reaching a ROI of 2.60 by the end of 2024.

smart-clot-img1.png

smart-clot-img2.jpg